Hong Kong stocks surged | BeiGene (06160.HK) rose nearly 3%, recently received FDA approval for Sutent in the US, with the company's first-quarter net profit exceeding market expectations.

According to equal ocean financial APP, BeiGene (06160.HK) rose by nearly 3%, as of the time of publication, it rose by 2.23%, to 178.7 Hong Kong dollars, with a trading volume of 4.67 billion Hong Kong dollars.